UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...
In rheumatoid arthritis (RA), the identification of prognostic factors (PF) capable of predicting disease outcome, response to treatment or success of dose reduction is an important issue, as these ...